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Hodgkin's disease (HD) is a hematologic malignancy which
shows common features regardless of race, but racial differ-
ences may be considered with certain clinical characteritcs.
HD in Korea shows somewhat different characteristics when
compared to cases in Western countries. We evaluated the
clinical and histopathologic characteristics of HD, the out-
comes of various chemotherapy regimens, and prognostic
factors of HD in Korea. One hundred and five patients with
initial histopathologic diagnosis of Hodgkin's disease were
retrospectively reviewed 20 years after diagnosis at Yonsei
University College of Medicine. Nodular sclerosis was the
most common histopathogic subtype (41%) and mixed cel-
lularity was nearly as common (40%). The overall complete
remission rate (CR) was 87.6%. The disease-free survival
(DFS) and overall survival (OS) rate were 79.2% and 84.8%
at 5-years, 70% and 79.2% at 10- and 20-years. There were
no significant differences in CR rate and DFS, but OS rates
were significantly higher in m-BACOP and ABVD regimen.
Univariate analysis revealed that age, B-symptom, ECOG
scale, Ann Arbor stage, international prognostic index, and
serum β2-microglobulin level were significant prognostic
factors for both DFS and OS. Multivariate analysis demon-
strated that age, B symptoms, and ECOG scale were sig-
nificant prognostic factors for OS only. In conclusion, the
survival rates of HD patients in our center were superior to
those of previous reports in Korea and Western countries.
Considering the higher OS rate and decreased incidence of
side effects, the ABVD regimen may be recommended for
the initial treatment of Hodgkin's disease.
Key Words: Hodgkin's disease, twenty year survival, chemo-
therapy, Korea
INTRODUCTION
Hodgkin's disease (HD) is often considered a
curable disease since the chemotherapy combina-
tion MOPP (mechlorethamine, vincristine, procar-
bazine, and prednisolone) was introduced by De
Vita et al.1 De Vita and colleagues achieved a 50%
cure rate for advanced-stage HD patients using
this regimen. After the initial success of the MOPP
regimen, many combination chemotherapies were
introduced that improved survival rate and
reduced complications. Combinations such as
BCVPP (bleomycin, cyclophosphamide, vincris-
tine, procarbazine, and prednisone) or ChlVPP
(chlorambucil, vinblastine, procarbazine, and pre-
dnisone) have also been used with some success.
However, outcomes were not significantly im-
proved until the ABVD (doxorubicin, bleomycin,
vincristine, and dacarbazine) regimen was intro-
duced in 1975 by Bonadonna and colleagues.2 The
MOPP-ABV (cyclophosphamide, vincristine, pro-
carbazine, prednisone, doxorubin, bleomycin, and
vinblastine) hybrid regimen was tried in 1982 by
Vancouver group,3 and BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vin-
cristine, prednisone, and procarbazine) was intro-
duced by the German Hodgkin Study Group in
1993.
4
The ABVD or BEACOPP regimen was gene-
rally found to be superior to the others, especially
in advanced cases.5,6
HD in Korea shows somewhat different charac-
teristics when compared to cases in Western coun-
tries. However, there were few studies of long-
term survival and few studies that compared the
results of various chemotherapy regimens. Using
a twenty-year follow up, this study aimed to
evaluate clinical and histopathological charac-
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teristics, therapeutic outcomes of chemotherapy
regimens, and prognostic factors of HD.
MATERIALS AND METHODS
Patients
One hundred five patients with an initial histo-
pathologic diagnosis of HD were retrospectively
reviewed. These patients had been diagnosed at
the Yonsei University College of Medicine from
January 1985 to February 2005. The median follow
up duration was 83 (6-241) months.
Diagnosis and staging
A tissue biopsy was performed in all patients
for diagnostic purposes. The patients were clas-
sified according to the Rye histopathologic clas-
sification, which included measures of lympho-
cyte predominance (LP), nodular sclerosis (NS),
mixed cellurarity (MC), and lymphocyte depletion
(LD).
The Ann-Arbor staging system was used in this
study. Staging modalities were computed using
one of the following methods: tomographic scan
of the neck, chest, abdomen and pelvis, whole
body bone scan, gallium scan, positron emission
tomography (PET) scan, or bilateral bone marrow
aspiration with biopsy. Initial lactate dehydro-
genase (LDH), β2-microglobulin, erythrocyte sedi-
mentation rate (ESR), and albumin level were
measured. We used the LDH index because the
LDH upper normal value changes over time
depending on the method of measurement. The
LDH index is the ratio of patient's LDH level and
upper normal LDH level at that time.
Treatment
The patients were divided into 3 groups de-
pending upon the initial treatment modality: ra-
diation alone, chemotherapy alone, and combined
chemo-radiotherapy. The chemotherapy regimens
used were C-MOPP (cyclophosphamide, vincris-
tine, procarbazine, prednisone), ABVD, COPP-
ABV hybrid (cyclophosphamide, vincristine , pro-
carbazine, prednisone, doxorubin, bleomycin, and
vinblastine), m-BACOP (methotrexate, bleomycin,
adriamycin, cyclophosphamide, vincristine, pre-
dnisolone) and other regimens.
Criteria for response
Therapeutic response was defined based on the
WHO criteria. Complete response (CR) was de-
fined as the disappearance of all clinical evidence
of lymphoma by physical examination and
restaging work-up and no histologic evidence of
lymphoma if it had been found earlier on bone
marrow or spinal fluid examination. Partial
response (PR) was defined as a greater than 50%
reduction of the diameter of measurable tumor
lesions for at least 4 weeks. Stable disease was
defined as less than 50% response without pro-
gression of disease. Progressive disease (PD) was
defined as 25% increase in diameters of known
lesions or any sites of disease. Those with stable
or progressive disease were deemed to have no
response (NR).
Statistics
Comparison of characteristics was made using
a chi-square (χ2) test for the binary variables and
a Mann-Whitney test for the continuous variables.
The logistic regression was used to test the rela-
tionship between continuous variables and sur-
vival. The disease-free survival (DFS) and overall
survival (OS) probabilities were calculated using
the Kaplan-Meier method. Univariate association
between the clinical features and DFS or OS was
determined by the log-rank test. Multivariate ana-
lysis was used to test for the independent pro-
gnostic significance of variables using the Cox
proportional hazards regression model. A p-value
< 0.05 was used to indicate statistical significance.
All calculations were performed using the SPSS
software, version 11.0.1 (SPSS Inc, Chicago, IL,
USA).
RESULTS
Patient characteristics
A total of 105 adults with newly diagnosed HD
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were enrolled in this study. Males were affected
more often than females (1.84 : 1), and the median
age of patients was 35 years (range, 5 to 88 years).
The clinical characteristics of the patients are
shown in Table 1.
Nodular sclerosis was the most common histo-
pathogic subtype (41%) and the mixed cellularity
(40%) was nearly as common. Eighty-six patients
(81.9%) were beyond stage I according to the
Ann-Arbor staging system.
The most common presenting symptom at the
time of diagnosis was lymphadenopathy (89.5%).
Cervical lymphadenopathy was the most common
type (75.2%). B symptoms were present in 29.5%
of the patients (Table 2).
The median follow-up duration was 53 months
for DFS and 59 months for OS.
Therapeutic outcomes
Therapeutic modalities used in this study are
summarized in Table 3. Radiotherapy alone was
used in 34 patients, chemotherapy alone in 38
patients, and combined chemo-radiotherapy in 33
patients. Of the 34 patients who received radio-
therapy, 33 patients had stage I or II disease and
1 had stage III. Of the 63 patients with stage I or
II disease and 41 patients with stage III disease,
30 received chemotherapy. Radiotherapy was
added for patients who had a bulky mass or who
showed suspicious residual lesions after chemo-
therapy. In 71 patients with chemotherapy and
combined chemo-radiotherapy, the COPP-ABV
hybrid regimen was used in 29 patients (40.8%),
and ABVD regimen in 19 patients (26.8%).
Complete response (CR) was achieved in 92
Table 1. The Characteristics of 105 Patients
Clinical parameters No. (%)
Age (yr) median [range] 35 5 - 88
Sex (M/F) 68/37 64.8/35.2
ECOG
0 or 1 vs. 2 94/11 (89.5/10.5)
Serum lactic dehydrogenase index
1 × normal vs. > 1 × normal 52/30 (49.5/28.6)
NA 23 (21.9)
Albumin (g/dL)
3.5 vs. > 3.5 21/74 (20.0/70.5)
NA 10 (9.5)
ESR
1 × normal vs. > 1 × normal 60/45 (57.1/42.9)
β2-microglobulin
1 × normal vs. > 1 × normal 45/20 (42.9/19.0)
NA 40 (38.1)
International prognostic index
Low 65 (61.9)
Low intermediate 22 (21.0)
High intermediate 11 (7.3)
High 7 (7.3)
Histopathologic subtypes
Lymphocyte predominance 13 (12.4)
Nodular sclerosis 43 (41.0)
Mixed cellularity 42 (40.0)
Lymphocyte depletion 7 (6.7)
Stage
I 19 (18.1)
II 44 (41.9)
III 19 (18.1)
IV 23 (21.9)
NA, not assessed; ECOG, Eastern Cooperative Oncology Group;
ESR, erythrocyte sedimentation rate.
Table 2. Presenting Symptoms and Signs
Clinical presentation No. (%)
Lymphadenopathy 94 (89.5)
Cervical 79 (75.2)
Mediastinal 6 (5.7)
Axillary 5 (4.8)
Inguinal 3 (2.9)
Paraaortic 1 (1.0)
B symtoms 31 (29.5)
Other Symptoms* 6 (5.7)
Total 105 (100)
*Cough (2), both leg edema (2), both foot tingling sensation (1),
both leg pain (1), jaundice (1), right upper quadrant pain (1),
dyspnea (1), left arm pain (1).
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patients (87.6%). The CR rate was 91.2% in the ra-
diotherapy group, 76.3% in chemotherapy group,
and 97% in combined chemo-radiotherapy group
(p = 0.489, Table 3). Among 92 patients who
achieved CR, 18 patients had a recurrence of HD.
The overall relapse rate was 17.4%, and the radio-
therapy group showed significantly higher relapse
rate than other two groups (p < 0.0001, Table 3).
In the chemotherapy group and combined chemo-
radiotherapy group, neither the CR rate nor the
relapse rate was significantly different based upon
which chemotherapeutic regimen was used (Table
4).
The DFS rate among the 92 patients who
showed CR was 85.5% at 2-years, 79.2% at 5-years
and 70.0% at 10- and 20-years (Fig. 1A). OS rate
was 84.8% at 5-years and 79.2% at 10- and
20-years (Fig. 1B).
Fig. 2 shows the OS as it relates to the histologic
subtypes (A) and stages (B). The OS rate after 10
years was significantly lower in those with lym-
phocyte depleted type disease than in the other
subtypes (p = 0.01, 57.1% in LD vs. 76.6% in NS,
80.8% in LP, and 84.6 in MC). The 5-year OS was
Table 3. Initial Responses According to the Therapeutic Modalities
RTx CTx CTx + RTx p value
CR 31/34 (91.2%) 29/38 (76.3%) 32/33 (97.0%) 0.489
Relapse 14/31 (45.2%) 2/29 (6.9%) 2/32 (6.3%) < 0.0001*
*between RTx and other two groups.
RTx, radiotherapy; CTx, chemotherapy; CTx+RTx, combined chemo-radiotherapy; CR, complete response.
Fig. 1. Disease-free survival rate (A) and overall survival rate (B).
Table 4. Initial Responses According to the Chemotherapeutic Regimens
C-MOPP ABVD COPP-ABV m-BACOP p value
CR 11/13 (84.6%) 13/15 (86.7%) 23/27 (85.2%) 10/10 (100%) 0.844
Relapse 1/11 (9.1%) 1/13 (7.7%) 2/23 (8.7%) 0/10 (0%) 0.393
CR, complete response; C-MOPP, cyclophosphamide, vincristine, procarbazine, and prednisolone; ABVD, doxorubicin, bleomycin,
vinblastine, and dacarbazine; COPP-ABV, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubin, bleomycin, and vinblas-
tine; m-BACOP, methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisolone.
A B
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88.9% in stage I, 88.3% in stage II, 78.7% in stage
III, and 69.1% in stage IV. The OS rate was sig-
nificantly decreased by the progression of stages
(p = 0.04, Fig. 2B).
Relapse rate was 45.2% in the radiotherapy
group, 6.9% in chemotherapy group, and 6.3% in
combined chemo-radiotherapy group. Among 14
patients who relapsed in radiotherapy group, 6
patients had stage 1 disease and 8 had stage 2
disease, and the MC was the most frequent sub-
type (8 cases). In early stages (stage I and II),
patients who received chemotherapy alone showed
higher DFS rate than those who received radio-
therapy alone but the difference was not statisti-
cally significant (Fig. 3A). The relatively high
relapse rate of the radiotherapy group and the
combined chemo- radiotherapy may be explained
by poor prognostic factors found in the early
stages of their disease. In advanced stages, there
were no significant differences in DFS among the
three treatment groups (Fig. 3B). Both 10- and
20-year DFS rate were 100% in m-BACOP, 90% in
ABVD, 86.8% in COPP/ABV, and 90.9% in C-
MOPP. The DFS rates did not differ significantly
among the chemotherapeutic regimens (Fig. 3C).
Although there were no statistically significant
differences in OS rates among the three different
treatment groups, the combined chemo-radio-
therapy group showed a higher OS rate than other
two groups (Fig. 4A). In early stages (stage I and
II), there were no significant differences in OS rate
among the three treatment groups (Fig. 4B). In
advanced stages, the patients who received com-
bined chemo-radiotherapy showed a higher OS
rate than those who received chemotherapy alone
but the difference was not statistically significant
(Fig. 4C). The 10- and 20-year OS rate were 100%
in m-BACOP, 93.3% in ABVD, 76.6% in COPP/
ABV, and 65.3% in C-MOPP. In chemotherapy or
combined chemo-radiotherapy groups, the ABVD
and m-BACOP regimen showed a better OS rate
than the COPP-ABV hybrid or C-MOPP regimen
(Fig. 4B), The OS rate of the patients with ABVD
regimen was significantly higher than that of the
patients who had the COPP-ABV hybrid regimen
(p = 0.03). For the twenty-year follow-up period,
17 patients (16.2%) were deceased. The primary
causes of death were disease progression (58.8%)
and infectious complications (17.6%).
Prognostic factors
Many pretreatment features such as age, sex,
B-symptom, extranodal involvement, stage, ECOG
scale, serum LDH level, serum β2-microglobulin
level, serum albumin level, and international
Fig. 2. (A) Overall survival rates according to the histological subtypes of the patients; LP, lymphocyte predom-
inance; NS, nodular sclerosis; MC, mixed cellurarity; LD, lymphocyte depletion. (B) Overall survival rates according
to the Ann-Arbor stage.
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prognostic index were introduced as prognostic
factors in HD.
In the current study, univariate analysis re-
vealed that high ECOG scale ( 2) and β2 micro-
globulin level consistently favored a poor pro-
gnosis for CR, DFS and OS. Old age (> 60), the
presence of B symptom, advanced stage ( III),
high IPI and lymphocyte depletion subtypes also
favored a poor prognosis for CR and OS, but not
for DFS. LDH level was also a significant pro-
gnostic factor for CR (Table 5).
Multivariate analysis of covariates in the Cox
regression model demonstrated that age, the pres-
ence of B-symptom, lymphocyte depletion sub-
types, and ECOG scale remained as independent
prognostic factors for CR and OS (Table 6).
DISCUSSION
Hodgkin's disease, firstly described by Sir
Thomas Hodgkin in 1832, is a lymphoid tumor
that represents 1% of all de novo malignancies
occurring yearly, worldwide. Although patients
with advanced stages of HD were considered
incurable until the middle of the 20th century,
there have been great strides in the management
of HD due to the availability of effective chemo-
therapy regimens, the use of combined chemora-
diotherapy with field irradiation in patients with
early-stage disease, the introduction of effective
salvage treatment with peripheral blood stem cell
transplantation for relapse HD, a better under-
standing of prognostic factors, and a more sensi-
Fig. 3. Disease-free survival rates according to the initial
treatment modalities in patients with early stage (A), and
in patients with advanced stage disease (B). (C) Disease-
free survival rates according to the chemotherapy regi-
mens. CTRT, combined chemo-radiotherapy; CT, chemo-
therapy; RT, radiotherapy; C-MOPP, cyclophosphamide,
vincristine, procarbazine, and prednisolone; ABVD,
doxorubicin, bleomycin, vinblastine, and dacarbazine;
COPP-ABV, cyclophosphamide, vincristine, procarbazine,
prednisone, doxorubin, bleomycin, and vinblastine; m-
BACOP, methotrexate, bleomycin, adriamycin, cyclo-
phosphamide, vincristine, and prednisolone.
A B
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tive realization of latetreatment-related mor-
bidity.
HD in Korea shows somewhat different char-
acteristics when compared with cases in Western
countries. The incidence of Hodgkin's disease
among all malignant lymphomas was 35-50% in
Western countries, and 8.6-17.8% in Korea.4-9
According to the literature, mixed cellulariy is
the most frequent histologic type in HD.
7,9,10
Park
et al. reported in 1999 that mixed cellularity is
found in 38% of cases and nodular sclerosis is
found in 28%.
10
In this study, nodular sclerosis
subtype (41%) had slightly higher incidence than
mixed cellularity (40%), and It presented with dif-
ferent clinical characteristics compared to several
previous studies. This change in subtypes of HD
in Korea may be interpreted as a westernized
phenomenon of HD.
Ryoo et al. and Ahn et al. reported 71.4% and
82% CR rate and a 59% and 66.6% of 5-year sur-
vival rate, respectively.11,12 Park et al. reported a
72.9% 3-year survival rate in 39 patients.10 In the
current study, the overall CR rate in response of
the initial therapy was 87.6%. The DFS and OS
Fig. 4. Overall survival rates according to the initial treatment modalities in the total population (A), in patients with
early stage (B), and in patients with advanced stage disease (C). (D) Overall survival rates according to the chemo-
therapy regimens. CTRT, combined chemo-radiotherapy; CT, chemotherapy; RT, radiotherapy; C-MOPP, cyclophospha-
mide, vincristine, procarbazine, and prednisolone; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; COPP-
ABV, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubin, bleomycin, and vinblastine; m-BACOP,
methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisolone.
B
D
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rate were 85.8% and 88.8% at 3 years, 79.2% and
84.8% at 5 years, and 70% and 79.2% from 10 to
20 years. According to the accumulated experi-
ence of Western countries, the CR rate ranged
from 73-92%, and the OS rate varies from 80% to
89% at 5 years.1,13 Compared with other studies in
Korea, this study, which contains the largest num-
ber of enrolled patients and the longest follow-up
duration, showed better CR, DFS, and OS rates,
and results comparable to those of Western coun-
tries.
The chemotherapy regimens used to treat HD
vary, as do the outcomes. Ahn et al. reported an
82% CR rate and a 66.6% 5-year survival rate in
28 patients using the COPP/ABV hybrid regi-
men.12 Jung et al. reported that 71.4% patients
achieved CR and 50.3% of patients achieved 5-
year survival among 28 patients with the C-MOPP
regimen.14 Longo et al. reported that, among the
complete response group, 64% cases were disease-
free and the overall survival rate was 48% in a
20-year follow-up study of MOPP therapy.15
Morgenield et al. reported that 66% of cases
achieved CR and had a 48-month median survival
time in COPP combined chemotherapy regi-
mens.16 Bonaddona et al. developed the ABVD
Table 5. Univariate Analysis of Patients Characteristics for Complete Remission, Disease-Free Survival, and Overall
Survival
Characteristics
CR DFS OS
Rate (%) p value Rate (%) p value Rate (%) p value
Age ( 60 vs. > 60, yrs) 81.7 vs. 30.8 < 0.001 73.2 vs. 51.4 0.1169 84.6 vs. 19.2 < 0.001
Male vs. Female 76.6 vs. 75 0.508 77.7 vs. 61.8 0.0556 78.2 vs. 75.9 0.717
B symptom* 61.8 vs. 81.9 0.021 79.5 vs. 68.9 0.8364 67.6 vs. 90.9 0.029
Extranodal Involvement* 67.6 vs. 79.5 0.130 91.6 vs. 66.2 0.2088 75.2 vs. 88 0.0895
Stage (I/II vs. III/IV) 86.6 vs. 62 0.002 85.3 vs. 66.3 0.2807 87.2 vs. 60.8 0.0092
ECOG (0-1 vs. 2-4) 83.5 vs. 21.4 < 0.001 74.3 vs. 34.3 0.0054 85.5 vs. 23.6 < 0.001
Serum LDH index 86.8 vs. 71.4 0.011 60.4 vs. 87.4 0.3714 89.6 vs. 75.2 0.1476
β2-microgobulin 87.5 vs. 52.2 0.002 87.1 vs. 56.4 0.0046 94.1 vs. 44.4 < 0.001
Albumin ( 3.5 vs. > 3.5 g/dL) 72.7 vs. 79.7 0.327 86.3 vs. 77.2 0.7159 76.7 vs. 81.9 0.2824
IPI 0.001 0.361 < 0.001
Low 89.5 69 93.7
Low intermediate 73.1 82 76.9
High intermediate 45.5 29.6 51.9
High 25 20.2 18.8
Histopathologic subtype 0.001 0.354 0.033
LP 100 92.3 84.6
NS 83.7 75 83.7
MC 95.2 80 88.1
LD 57.1 100 57.1
CR, complete response; DFS, disease-free survival; OS, overall survival; LDH, lactic dehydrogenase; ECOG, Eastern Cooperative
Oncology Group; IPI, international prognostic index; LP, lymphocyte predominance; NS, nodular sclerosis; MC, mixed cellularity;
LP, lymphocyte depletion.
*Present vs. Absent.
1 vs. > 1 × normal.
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regimen and reported that the results of ABVD
alone or an alternating regimen of MOPP and
ABVD were similar to the MOPP regimen.17-19
Glick et al. reported that the MOPP/ABV hybrid
regimen was superior to the sequential MOPP-
ABVD regimen.20
In the current study, chemotherapy with vari-
ous regimens was performed in 81 cases, and the
therapeutic outcomes were different depending on
the chemotherapy regimens. The ABVD regimen
had a 86.7% CR rate and a 93.3% 5-year OS rate.
The COPP/ABV hybrid regimen showed an 85.2%
CR rate and an 87.5% 5-year OS rate. The C-
MOPP regimen showed a 84.6% CR rate and a
65.3% 5-year OS rate. The 20-year rates of DFS
and OS respectively, as with the 10-year, were
90% and 93.3% in ABVD, 76.6% and 86.8% in
COPP/ABV, and 65.3% and 90.9% in C-MOPP.
The OS rate of patients with the ABVD regimen
was significantly higher than that of patients with
the COPP-ABV hybrid regimen (p = 0.03). All of
these survival rates were superior to those found
among previous reports in Korea, and even those
of Western reports.17-21
Among the various chemotherapy regimens,
the ABVD regimen was deemed superior overall.
These results were similar to those of Bonaddona
et al.17-19 According to a recent report by
Bonaddona, after a median follow-up of 25 years,
freedom from progression was found in 46% of
patients after MOPP and 58% after ABVD, sug-
gesting a relative reduction of approximately
30% favoring the ABVD arm. For both treatment
regimens, the vast majority of failures were
observed during the first 5 years of chemo-
therapy, and no deaths caused by progressive
lymphoma were documented after 12 years from
starting either MOPP or ABVD.21 Therefore,
ABVD regimen with or without radiotherapy is
recommended as the treatment of choice for HD.
ABVD regimen has lower side-effect incidence of
azospermia (less than 20%) or prolonged amen-
orrhea (fewer than 5%)22 and a lower risk of
inducing secondary leukemia or myelodysplastic
syndrome21 as well as greater therapeutic po-
tency.
According to recent Western reports, the role of
newer and more intensified combined treatment
regimens such as escalating BEACOPP have been
emphasized,
23
but these still have a higher risk of
treatment-related complications and need to be
evaluated by large-scale randomized studies with
long-term follow up.
In previous studies of Hodgkin's disease, vari-
ous pretreatment factors were associated with
therapeutic outcomes. Alessandro et al. reported
that CR rate was significantly associated with his-
tologic type and ERC (early response to chemo-
therapy),24 and other studies in Western countries
reported that age, ESR, histopathologic subtype,
and mediastinal lymph node involvement could
influence therapeutic outcomes.25-27 Park et al.
reported that age, performance status, serum
albumin level, and serum LDH level were signifi-
Table 6. Multivariate Analysis of Prognostic Factor
Factors CR DFS OS
Age ( 60 vs. > 60, yrs) 0.007 0.431 0.005
B symptom (present vs. absent) 0.049 0.528 0.008
ECOG (0 - 1 vs. 2 - 4) 0.006 0.093 < 0.001
Stage (I/II vs. III/IV) 0.048 0.155 0.086
Histopathologic subtypes 0.033 0.071 0.005
IPI (L, LI, HI, H) 0.360 0.640 0.572
Serum albumin ( 1 vs. > 1 × normal) 0.892 0.494 0.271
ESR ( 1 vs. > 1 × normal) 0.775 0.945 0.408
CR, complete response; DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; IPI, international
prognostic index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; ESR, erythrocyte sedimentation rate.
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cant prognostic factors when evaluated by uni-
variate analysis, but multivariate analysis showed
that only performance status was a statistically
significant prognostic factor.10 Hahn et al. reported
that there is no significant prognostic factor in
Hodgkin's disease among Korean people.9
In our study, univariate analysis revealed that
high ECOG scale ( 2) and β2-microglobulin level
were significant factors of a bad prognosis for CR,
DFS, and OS. Old age (> 60), the presence of B
symptom, advanced stage ( III), high IPI, and
lymphocyte depletion subtypes were poor pro-
gnostic factors for CR and OS though not for DFS.
LDH level was an additional prognostic factor for
CR (Table 5).
Multivariate analysis of covariates in the Cox
regression model demonstrated that age, the
presence of B-symptom, lymphocyte depletion
subtypes, and ECOG scale remained independent
prognostic factors of CR and OS (Table 6).
According to our study, ABVD regimen with or
without radiotherapy might be considered the
treatment of choice for HD because of the superior
long-term survival benefit. Although the analysis
about complications of treatment in relation to the
various chemotherapy regimens was not per-
formed, the ABVD regimen is recommended in
the treatment for Hodgkin's disease due to the
relatively low incidence of infertility and leuke-
mogenic risk. Furthermore, continuous long-term
follow-up will be needed to evaluate long term
complications of each chemotherapy regimen.
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